Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins (US5977307)

1996-11-26	US1996000581543
1993-07-16	US1993000094534
1992-11-20	US1992000999803
1992-03-06	US1992000846830
1990-09-07	WO1990US0005077
1989-09-07	US1989000404089

Abstract:

PCT No. PCT/US95/01469 Sec. 371 Date Nov. 26, 1996 Sec. 102(e) Date Nov. 26, 1996 PCT Filed Feb. 3, 1995 PCT Pub. No. WO95/21245 PCT Pub. Date Aug. 10, 1995The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is reactive with a brain capillary endothelial cell receptor. Other aspects of this invention include a delivery system comprising a ligand reactive with a brain capillary endothelial cell receptor which has formed a fusion protein with a neuropharmaceutical agent. The fusion proteins are also aspects of this invention.

Attorney, Agent or Firm:

Hamilton Brook Smith & Reynolds, P.C. ;

Primary / Asst. Examiners:

Caputa, Anthony C.; Navarro, Mark

INPADOC Legal Status:

Show legal status actions Buy Now: Family Legal Status Report

Related Applications:

Application Number	Filed	Pub. Date	Title
US1993000094534	1993-07-16	1997-09-30	Transferrin neuropharmaceutical agent fusion protein
US1992000999803	1992-11-20
US1992000846830	1992-03-06	1993-01-26	Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US1990000005077	1990-09-07
US1989000404089	1989-09-07	1992-10-13	Transferrin receptor specific antibody-neuropharmaceutical agent conjugates


	Parent Case:			RELATED APPLICATIONS This Application is the U.S. National Phase of PCT/US94/08000, filed Jul. 18, 1994, which is a Continuation-in-Part of U.S. Ser. No. 08/094,534, filed Jul. 16, 1993, now U.S. Pat. No. 5,672,683 which is Continuation-in-Part of Ser. No. 07/999,803, filed Nov. 20, 1992 (now abandoned), which is a Divisional of Ser. No. 07/846,830, filed Mar. 6, 1992 (now U.S. Pat. No. 5,182,107), which is a Continuation-in-Part of PCT/US90/05077, filed Sep. 7, 1990, which is a Continuation-in-Part of U.S. Ser. No. 07/404,089, filed Sep. 7, 1989 (now U.S. Pat. No. 5,154,924, issued Oct. 13, 1992).
	Designated Country:			AM AP BB BG BR BY CN CZ FI GE HU KE KG KP KR KZ LK LT LV MD MG MN BE CH DK FR GB GR IE IT LI LU MC
	Family:			Show 43 known family members
	First Claim: Show all 6 claims			We claim: 1. A fusion protein comprising a brain capillary endothelial cell receptor ligand and a neuropharmaceutical agent wherein: (a) the neuropharmaceutical agent consists of nerve growth factor (NGF), and (b) the ligand is selected from the group consisting of transferrin, insulin, an antibody to the transferrin receptor, an antibody to insulin-like growth factor 1 (IGF 1) receptor, an antibody to insulin-like growth factor 2 (IGF 2) receptor and an antibody to insulin receptor; wherein the ligand and the neuropharmaceutical agent are linked through an intermediate peptide or polypeptide.
	Background / Summary:			Show background / summary
	Drawing Descriptions:			Show drawing descriptions
	Description:			Show description
	PCT Number:			PCT/US95/01469 WO9521245
	PCT Pub./Filed Dates:			1995-08-10 / 1995-02-03
	§ 371 / 102(e) Dates:			1996-11-26 / 1996-11-26
	Forward References:			Show 40 U.S. patent(s) that reference this one

U.S. References:

Go to Result Set: All U.S. references | Forward references (40) | Backward references (23) | Citation Link

Patent	Pub.Date	Inventor	Assignee	Title
US4292425	1981-09	Buckler et al.	Miles Laboratories, Inc.	βGalactosyl-umbelliferone valproic acid conjugates
US4434156	1984-02	Trowbridge	The Salk Institute for Biological Studies	Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4444744	1984-04	Goldenberg		Tumor localization and therapy with labeled antibodies to cell surface antigens
US4545985	1985-10	Pastan et al.	The United States of America as represented by the Secretary, Dept. of Health and Human Services	Pseudomonas exotoxin conjugate immunotoxins
US4569789	1986-02	Blattler et al.	Dana-Farber Cancer Institute, Inc.	Acid-cleavable compound, use in protein conjugates and drug delivery systems
US4626507	1986-12	Trowbridge et al.	The Salk Institute for Biological Studies	Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4631190	1986-12	Shen et al.		Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4801575	1989-01	Padridge	The Regents of the University of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4816567	1989-03	Cabilly et al.	Genentech, Inc.	Recombinant immunoglobin preparations
US4886780	1989-12	Faulk		Conjugates of apotransferrin proteins with anti-tumor agents
US4892827	1990-01	Pastan et al.	The United States of America as represented by the Department of Health and Human Services	Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4902505	1990-02	Padridge et al.	Alkermes	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4992255	1991-02	Pardridge		Capillary depletion method for quantifying transcytosis through the blood-brain barrier
US5004697	1991-04	Pardridge	Univ. of CA	Cationized antibodies for delivery through the blood-brain barrier
US5026651	1991-06	Bowman et al.	Board of Regents, The University of Texas System	Methods and compositions for the production of human transferrin
US5028697	1991-07	Johnson et al.	Eli Lilly and Company	Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5087616	1992-02	Myers et al.	Battelle Memorial Institute	Cytotoxic drug conjugates and their delivery to tumor cells
US5091513	1992-02	Huston et al.	Creative BioMolecules, Inc.	Biosynthetic antibody binding sites
US5108987	1992-04	Faulk		Conjugates of proteins with anti-tumor agents
US5130129	1992-07	Pardridge	The Regents of the University of California	Method for enhancing antibody transport through capillary barriers
US5132405	1992-07	Huston et al.	Creative BioMolecules, Inc.	Biosynthetic antibody binding sites
US5141736	1992-08	Iwasa et al.	Takeda Chemical Industries, Ltd.	Bispecific monoclonal antibody, its production and use
US5330971	1994-07	Wells et al.	GroPep Pty. Ltd.	Growth hormone fusion proteins, methods of production, and methods of treatment

Foreign References:

Publication	Date	IPC Code	Assignee	Title
EP0094844	1983-11	A61K 47/00	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	Drug-carrier conjugates
EP0175560	1986-03	G01N 33/535	E.I. DU PONT DE NEMOURS AND COMPANY	Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
EP0253202	1988-01	A61K 39/395	ONCOGEN	Novel immunoconjugates and methods for their use in tumor therapy
EP0286418	1988-10	A61K 9/50	THE UNITED STATES OF AMERICA represented by The Secretary The United States Department of Commerce	Anti-retroviral agents and delivery systems for the same
EP0286441	1988-10	A61K 35/78	ZYMOGENETICS INC	Novel cytotoxic protein
EP0305967	1989-03	A61K 45/02	CIBA GEIGY AG	Conjugates of cytokines with immunoglobulins
EP0324625	1989-07	A61K 39/385	Bunge (Australia) Proprietary Limited	Antigen antibody conjugate
EP0327169	1989-08	A61K 47/00	AKZO N.V.	Immunotoxins from barley toxin
EP0328147	1989-08	A61K 47/00	Bristol-Myers Company	Anthracycline immunoconjugates having a novel linker and methods for theirproduction
EP0336383	1989-10	A61K 47/48	TAKEDA CHEMICAL INDUSTRIES, LTD.	Novel recombinant human lymphotoxin
EP0449769	1991-10	A61K 38/00	ROYAL FREE HOSP SCHOOL MED	CD 25 binding molecules
GB1564666	1980-04	A61K 38/00	FUNG KWOK PUI	HETEROCOMPLEXES OF INTERFERON WITH IMMUNOGLOBULIN AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO8601409	1986-03	A61K 39/00	DANA FARBER CANCER INST INC	ACID-CLEAVABLE COMPOUND
WO8807365	1988-10	A61K 9/16	RANNEY, David, F.	BIODADHESION DRUG CARRIERS FOR ENDOTHELIAL AND EPITHELIAL UPTAKE AND LESIONAL LOCALIZATION OF THERAPEUTIC AND DIAGNOSTIC AGENTS
WO9103259	1991-03	A61K 39/395	ALKERMES INC	TRANSFERRIN RECEPTOR SPECIFIC ANTIBODY-NEUROPHARMACEUTICAL AGENT CONJUGATES
WO9104753	1991-04	A61K 47/48	CETUS CORPORATION	CONJUGATES OF ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTIC USES THEREOF
WO9109965	1991-07	A61K 38/00	THE UNITED STATES OF AMERICA, represented by THE ...	AN IMPROVED TOXIN FOR CONSTRUCTION OF IMMUNOTOXINS
WO9213570	1992-08	A61K 47/48	BIRNSTIEL, Max, L.	NOVEL COMPLEXES CONTAINING NUCLEIC ACID WHICH CAN BE ABSORBED INTO HIGHER EUCARYOTIC CELLS VIA ENDOCYTOSIS
WO9310819	1993-06	A61K 47/48	ALKERMES, INC.	PROCESS FOR THE PREPARATION OF TRANSFERRIN RECEPTOR SPECIFIC ANTIBODY-NEUROPHARMACEUTICAL OR DIAGNOSTIC AGENT CONJUGATES